Clinical Trials Logo

Clinical Trial Summary

This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02614846
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact Yu Hu, Ph.D
Email dr_huyu@126.com
Status Recruiting
Phase Phase 1
Start date August 2015

See also
  Status Clinical Trial Phase
Completed NCT00540423 - Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT00504075 - A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT04071496 - Diagnostic of Chronic Thrombocytopenia
Completed NCT00467571 - Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Phase 4
Completed NCT00441090 - Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 2